The Efficacy of Arterial Embolization in Patients with a Renal Cell Carcinoma.
- Author:
Kyu Il AHN
1
;
Seung Hyun JEON
;
Sung Goo CHANG
Author Information
1. Department of Urology, Kyung Hee University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Renal cell carcinoma;
Therapeutic embolization;
Immunotherapy
- MeSH:
Carcinoma, Renal Cell*;
Disease Progression;
Embolization, Therapeutic;
Follow-Up Studies;
Hematuria;
Humans;
Immunotherapy;
Interferons;
Interleukin-2;
Isotretinoin;
Prognosis;
Survival Rate
- From:Korean Journal of Urology
2005;46(2):118-123
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We evaluated the efficacy of an arterial embolization in patients with a renal cell carcinoma. MATERIALS AND METHODS: We studied 17 patients with a renal cell carcinoma that underwent a transcatheter arterial embolization between 1995 and 2004. We studied the patients' character, performance status (ECOG), tumor location, size, stage, symptoms, cause of embolization, prognosis, and survival rate, as well as the follow up period. Patients were classified into three groups: group (I) consisted of patients where the procedure was performed with an angioinfarction only; group (II) consisted of patients where the procedure was performed with an angioinfarction, followed by additional immunotherapy with interferon; group (III) consisted of patients where the procedure was performed with an angioinfarction, followed by additional immunotherapy with interleukin-2, interferon, 5-flourouracil, 13-cis-retinoic acid and H2-blocker. RESULTS: The patients' ECOG (Eastern Co-operative Oncology Group criteria) scores were 1, 2, 3 and 4 in 2, 6, 6 and 3 patients, respectively. After the transcatheter arterial embolization, symptomatic improvement of the hematuria and pain were observed. All patients had disease progression, with the exception of one stable disease. Group I had a better survival than groups II or III (p=0.036). CONCLUSIONS: Transcatheter arterial embolization is a safe treatment for patients with a renal cell carcinoma where an operation is unavailable due to a poor performance status or advanced stage. The procedure may not influence the survival rate, but does improve the symptoms; additional immunotherapy may not improve the survival rate either.
